Elizabeth Marlowe, Ph.D., D(ABMM), is the Scientific Director and Head of R&D for Quest Diagnostics Infectious Diseases. She received her Ph.D. from the University of Arizona in 1999 and completed a clinical and public health microbiology postdoctoral fellowship in 2001 at the UCLA David Geffen School of Medicine.

After her fellowship, Marlowe continued as an adjunct professor and research coordinator at the Wadsworth Anaerobe Laboratory, where her research focused on the microbiome of the autistic gut and the role of toxin-producing anaerobes. In 2002, she joined Gen-Probe with her primary research in the development of rapid molecular diagnostics for infectious diseases. Her team conducted some of the initial prototype and assay feasibility work on the Panther Fusion System.

From 2005-2016, Marlowe provided laboratory leadership within the Kaiser Permanente Regional Laboratories in both Southern California, as the assistant director, and Northern California, as director of microbiology. At Kaiser, she oversaw the translational research program that included participation in >10 clinical trials.

From 2016-2019, Marlowe held the position of Global Director of Medical Affairs at Roche Molecular Systems, where she supported several product launches including the cobas CT/NG, TV/MG, MTB, MAI & RIF/INH assays. At Quest, her team has led the diagnostic testing efforts for the coronavirus pandemic.

Marlowe is a Diplomate of the American Board of Medical Microbiology, past President for Southern California ASM, past Editor for the Clinical Microbiology Newsletter and an inaugural member of the Council on Microbial Sciences for ASM. She has served as a member of CLIAC, the federal advisory committee for CLIA. Her research areas of interest are focused on the translation of new infectious disease diagnostics for use in evidence-based research for clinical microbiology practice.